CD47-Blocking Antibody Shows Promise as Novel Anti-Obesity Treatment
Researchers discover that blocking CD47 protein prevents weight gain and improves metabolism through muscle-specific AMPK activation.
Summary
Scientists found that blocking the CD47 protein with antibodies prevents obesity-related weight gain and metabolic dysfunction in mice. The treatment specifically activated AMPK energy sensors in skeletal muscle, leading to improved glucose tolerance, enhanced exercise capacity, and better body composition. Obesity increased CD47 levels while exercise decreased them, suggesting CD47 as a promising therapeutic target for metabolic disorders.
Detailed Summary
This groundbreaking study reveals that CD47-blocking antibodies, currently being tested for cancer treatment, may offer a novel approach to combating obesity and metabolic disorders. The research addresses the critical need for targeted therapies that can activate beneficial metabolic pathways without causing harmful side effects in other tissues.
Researchers studied mice fed high-fat diets and treated them with CD47-blocking antibodies every two days. They discovered that obesity increases CD47 expression in skeletal muscle, while regular exercise decreases it. This inverse relationship suggested CD47 might be a key regulator of metabolic health.
The antibody treatment produced remarkable results: mice showed reduced weight gain, improved body composition with less fat and more lean muscle mass, enhanced glucose tolerance, and significantly better exercise capacity. Importantly, the treatment specifically activated AMPK (AMP-activated protein kinase) in skeletal muscle but not in other tissues like fat, liver, or kidney. This tissue-specific activation is crucial because widespread AMPK activation can cause harmful effects like cardiac hypertrophy.
The mechanism involves CD47's interaction with heat shock protein 90α (HSP90α). When CD47 is blocked, HSP90α phosphorylation decreases, which then allows AMPK to become active. This activation improves mitochondrial function and energy metabolism specifically in muscle tissue, which comprises about 40% of body weight and plays a central role in whole-body metabolism.
These findings suggest CD47-blocking antibodies could potentially be repurposed from cancer therapy to treat obesity and related metabolic conditions. However, the research was conducted only in mice, and human trials would be necessary to confirm safety and efficacy. The tissue-specific nature of the effects makes this approach particularly promising for avoiding the side effects associated with current metabolic therapies.
Key Findings
- CD47-blocking antibody prevented weight gain and improved glucose tolerance in obese mice
- Treatment specifically activated AMPK in skeletal muscle without affecting other tissues
- Obesity increased CD47 expression while exercise decreased it in muscle tissue
- Antibody treatment enhanced exercise capacity and improved body composition
- Mechanism involves CD47-HSP90α pathway regulating AMPK activation
Methodology
Researchers used high-fat diet-induced obesity in mice, administering CD47-blocking antibodies subcutaneously every two days. They employed muscle-specific CD47 knockout mice to confirm tissue-specific effects and measured metabolic parameters including body composition, glucose tolerance, and exercise capacity.
Study Limitations
Study conducted only in mice; human efficacy and safety unknown. Long-term effects of CD47 blockade on immune function and other physiological processes require investigation. Translation from mouse metabolism to human metabolism may differ significantly.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.